Iovance Stock Plunges Amid Lung Cancer Treatment Questions Iovance Biotherapeutics' (IOVA) stock took a hit on Thursday, falling below its 50-day moving average, as investors raised concerns about the durability of its experimental lung cancer treatment, lifileucel. The treatment showed promise in a recent study, with a notable response rate among patients with metastatic lung cancer. However, the company failed to provide details on the length of patient responses or specific safety and tolerability results. The lack of clarity on these crucial aspects of the treatment has sparked investor skepticism, leading to a decline in Iovance's stock price. The company's inability to provide a clear picture of the treatment's effectiveness and safety has raised questions about its potential for long-term success. As a result, investors are reevaluating their bets on the biotech stock, which was previously considered a top performer in the industry. The uncertainty surrounding Iovance's lung cancer treatment has sent shockwaves through the biotech sector, with investors closely watching the company's next moves. The incident serves as a reminder of the high stakes involved in the development of life-saving treatments and the importance of transparency in reporting clinical trial results.